Wells Fargo Initiates Coverage On Korsana Biosciences with Overweight Rating, Announces Price Target of $44

Benzinga · 1d ago
Wells Fargo analyst Benjamin Burnett initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Overweight rating and announces Price Target of $44.